Pharmacokinetics of oxiracetam and its degraded substance (HOPAA) after oral and intravenous administration in rats

Nicolaus, 1982, Chemistry and pharmacological of nootropics, Drug Dev Res, 2, 463, 10.1002/ddr.430020507 Malykh, 2010, Piracetam and piracetam-like drugs from basic science to novel clinical applications to CNS disorders, Drugs, 70, 287, 10.2165/11319230-000000000-00000 Saletu, 1985, Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life, Neuropsychobiology, 13, 44, 10.1159/000118161 Banfi, 1986, Experimental behavioral studies with oxiracetam on different types of chronic cerebral impairment, Clin Neuropharmacol, 9, S19, 10.1097/00002826-198609003-00005 Huang, 2013, Evaluation of clinical effect of oxiracetam combined with nimodipine in treatment of vascular dementia in 49 cases, China Prac Med, 8, 36 Li, 2013, Protective effect of oxiracetam on traumatic brain injury in rats, Zhongguo Ying Yong Sheng Li Xue Za Zhi, 29, 298 Gagliardi, 1994, HPLC determination of oxiracetam, its impurities, and piracetam in pharmaceutical formulations, Anal Lett, 27, 879, 10.1080/00032719408007358 Wan, 2014, Simultaneous quantitative determination of oxiracetam and its degraded substance (HOPAA) in rat plasma by HPLC-MS/MS after a single high dose intravenous administration, J Chromatogr B, 969, 95, 10.1016/j.jchromb.2014.07.041 Perucca, 1984, Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers, Eur J Drug Metab Pharmacokinet, 3, 267, 10.1007/BF03189650 Liu, 1999, Pharmacokinetics of oxiracetam in rats and mice, Acta Pharmacol Sin, 34, 85 Liu, 2012, Effects of omeprazole on pharmacokinetics of oxiracetam in rats, China Pharm, 23, 1172